Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jun;84(11):1437–1442. doi: 10.1054/bjoc.2001.1819

Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer

R C F Leonard 1
PMCID: PMC2363663  PMID: 11384089

Abstract

Although drugs such as the taxoids and vinorelbine have increased the options available for anthracycline-resistant metastatic breast cancer, new therapeutic options are needed, particularly for taxoid-refractory tumours. Increasing emphasis is being placed on the development of oral agents, which many patients prefer provided efficacy is not compromised, particularly if the oral agents are less toxic than current intravenous agents. Capecitabine, a new, oral fluoropyrimidine, mimics continuous infusion 5-FU and is activated preferentially at the tumour site. Phase II studies of capecitabine have demonstrated encouraging response rates in patients with few further treatment options (20% response with an additional 43% achieving stable disease in paclitaxel-refractory patients; 36% response with a further 23% achieving stable disease in anthracycline-refractory patients). In addition, a randomized, phase II trial demonstrated a response rate of 30% (95% Cl: 19–43%) with capecitabine as first-line treatment for metastatic breast cancer, compared with 16% (95% Cl: 5–33%) in patients receiving low-dose CMF. These trials also showed that capecitabine has a favourable safety profile typical of infused fluoropyrimidines. Both alopecia and myelosuppression were rare. Capecitabine may therefore provide an effective, well-tolerated and convenient alternative to intravenous cytotoxic agents, not only in taxoid-resistant patients, but also in anthracycline-resistant metastatic breast cancer or as first-line therapy. Furthermore, the low incidence of myelosuppression makes capecitabine an attractive agent for incorporation into combination regimens with agents such as epirubicin/doxorubicin, the taxoids and vinorelbine. © 2001 Cancer ResearchCampaign http://www.bjcancer.com

Keywords: breast cancer, anthracyclines, capecitabine, 5-FU, taxoids, vinorelbine, oral

Full Text

The Full Text of this article is available as a PDF (72.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer C. D., Lowdell C., Sinnett H. D., English J., Khan S., Coombes R. C. Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. Eur J Cancer. 1998 May;34(6):816–819. doi: 10.1016/s0959-8049(97)10113-7. [DOI] [PubMed] [Google Scholar]
  2. Bishop J. F., Dewar J., Toner G. C., Tattersall M. H., Olver I. N., Ackland S., Kennedy I., Goldstein D., Gurney H., Walpole E. Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand. Oncology (Williston Park) 1997 Apr;11(4 Suppl 3):19–23. [PubMed] [Google Scholar]
  3. Blum J. L., Jones S. E., Buzdar A. U., LoRusso P. M., Kuter I., Vogel C., Osterwalder B., Burger H. U., Brown C. S., Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999 Feb;17(2):485–493. doi: 10.1200/JCO.1999.17.2.485. [DOI] [PubMed] [Google Scholar]
  4. Budman D. R., Meropol N. J., Reigner B., Creaven P. J., Lichtman S. M., Berghorn E., Behr J., Gordon R. J., Osterwalder B., Griffin T. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 1998 May;16(5):1795–1802. doi: 10.1200/JCO.1998.16.5.1795. [DOI] [PubMed] [Google Scholar]
  5. Carlson R. W. Quality of life issues in the treatment of metastatic breast cancer. Oncology (Williston Park) 1998 Mar;12(3 Suppl 4):27–31. [PubMed] [Google Scholar]
  6. Cassidy J., Dirix L., Bissett D., Reigner B., Griffin T., Allman D., Osterwalder B., Van Oosterom A. T. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res. 1998 Nov;4(11):2755–2761. [PubMed] [Google Scholar]
  7. Chan S., Friedrichs K., Noel D., Pintér T., Van Belle S., Vorobiof D., Duarte R., Gil Gil M., Bodrogi I., Murray E. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999 Aug;17(8):2341–2354. doi: 10.1200/JCO.1999.17.8.2341. [DOI] [PubMed] [Google Scholar]
  8. Cocconi G., Bisagni G., Bacchi M., Buzzi F., Canaletti R., Carpi A., Ceci G., Colozza A., De Lisi V., Lottici R. A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol. 1990;1(1):36–44. doi: 10.1093/oxfordjournals.annonc.a057671. [DOI] [PubMed] [Google Scholar]
  9. DeMario M. D., Ratain M. J. Oral chemotherapy: rationale and future directions. J Clin Oncol. 1998 Jul;16(7):2557–2567. doi: 10.1200/JCO.1998.16.7.2557. [DOI] [PubMed] [Google Scholar]
  10. Degardin M., Bonneterre J., Hecquet B., Pion J. M., Adenis A., Horner D., Demaille A. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol. 1994 May;5(5):423–426. doi: 10.1093/oxfordjournals.annonc.a058873. [DOI] [PubMed] [Google Scholar]
  11. Fumoleau P., Delgado F. M., Delozier T., Monnier A., Gil Delgado M. A., Kerbrat P., Garcia-Giralt E., Keiling R., Namer M., Closon M. T. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993 Jul;11(7):1245–1252. doi: 10.1200/JCO.1993.11.7.1245. [DOI] [PubMed] [Google Scholar]
  12. Hansen R., Quebbeman E., Beatty P., Ritch P., Anderson T., Jenkins D., Frick J., Ausman R. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat. 1987 Nov;10(2):145–149. doi: 10.1007/BF01810577. [DOI] [PubMed] [Google Scholar]
  13. Hortobagyi G. N., Piccart-Gebhart M. J. Current management of advanced breast cancer. Semin Oncol. 1996 Oct;23(5 Suppl 11):1–5. [PubMed] [Google Scholar]
  14. Huan S., Pazdur R., Singhakowinta A., Samal B., Vaitkevicius V. K. Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma. Cancer. 1989 Feb 1;63(3):419–422. doi: 10.1002/1097-0142(19890201)63:3<419::aid-cncr2820630303>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  15. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 1998 Feb 15;58(4):685–690. [PubMed] [Google Scholar]
  16. Ishikawa T., Utoh M., Sawada N., Nishida M., Fukase Y., Sekiguchi F., Ishitsuka H. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 1998 Apr 1;55(7):1091–1097. doi: 10.1016/s0006-2952(97)00682-5. [DOI] [PubMed] [Google Scholar]
  17. Jabboury K., Holmes F. A., Hortobagyi G. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer. 1989 Aug 15;64(4):793–797. doi: 10.1002/1097-0142(19890815)64:4<793::aid-cncr2820640404>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  18. Johnson M. R., Hageboutros A., Wang K., High L., Smith J. B., Diasio R. B. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999 Aug;5(8):2006–2011. [PubMed] [Google Scholar]
  19. Jones S., Winer E., Vogel C., Laufman L., Hutchins L., O'Rourke M., Lembersky B., Budman D., Bigley J., Hohneker J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995 Oct;13(10):2567–2574. doi: 10.1200/JCO.1995.13.10.2567. [DOI] [PubMed] [Google Scholar]
  20. Liu G., Franssen E., Fitch M. I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997 Jan;15(1):110–115. doi: 10.1200/JCO.1997.15.1.110. [DOI] [PubMed] [Google Scholar]
  21. Livingston R. B., Ellis G. K., Gralow J. R., Williams M. A., White R., McGuirt C., Adamkiewicz B. B., Long C. A. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997 Apr;15(4):1395–1400. doi: 10.1200/JCO.1997.15.4.1395. [DOI] [PubMed] [Google Scholar]
  22. Lu Z., Zhang R., Carpenter J. T., Diasio R. B. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res. 1998 Feb;4(2):325–329. [PubMed] [Google Scholar]
  23. Mackean M., Planting A., Twelves C., Schellens J., Allman D., Osterwalder B., Reigner B., Griffin T., Kaye S., Verweij J. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998 Sep;16(9):2977–2985. doi: 10.1200/JCO.1998.16.9.2977. [DOI] [PubMed] [Google Scholar]
  24. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., Shimma N., Umeda I., Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998 Jul;34(8):1274–1281. doi: 10.1016/s0959-8049(98)00058-6. [DOI] [PubMed] [Google Scholar]
  25. Nabholtz J. M., Senn H. J., Bezwoda W. R., Melnychuk D., Deschênes L., Douma J., Vandenberg T. A., Rapoport B., Rosso R., Trillet-Lenoir V. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999 May;17(5):1413–1424. doi: 10.1200/JCO.1999.17.5.1413. [DOI] [PubMed] [Google Scholar]
  26. Ng J. S., Cameron D. A., Leonard R. C. Infusional 5-fluorouracil in breast cancer. Cancer Treat Rev. 1994 Oct;20(4):357–364. doi: 10.1016/0305-7372(94)90017-5. [DOI] [PubMed] [Google Scholar]
  27. Pronk L. C., Vasey P., Sparreboom A., Reigner B., Planting A. S., Gordon R. J., Osterwalder B., Verweij J., Twelves C. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer. 2000 Jul;83(1):22–29. doi: 10.1054/bjoc.2000.1160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ray-Coquard I., Biron P., Bachelot T., Guastalla J. P., Catimel G., Merrouche Y., Droz J. P., Chauvin F., Blay J. Y. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer. 1998 Jan 1;82(1):134–140. [PubMed] [Google Scholar]
  29. Romero A., Rabinovich M. G., Vallejo C. T., Perez J. E., Rodriguez R., Cuevas M. A., Machiavelli M., Lacava J. A., Langhi M., Romero Acuña L. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 1994 Feb;12(2):336–341. doi: 10.1200/JCO.1994.12.2.336. [DOI] [PubMed] [Google Scholar]
  30. Schiff P. B., Horwitz S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561–1565. doi: 10.1073/pnas.77.3.1561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Schüller J., Cassidy J., Dumont E., Roos B., Durston S., Banken L., Utoh M., Mori K., Weidekamm E., Reigner B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45(4):291–297. doi: 10.1007/s002800050043. [DOI] [PubMed] [Google Scholar]
  32. Seidman A. D., Tiersten A., Hudis C., Gollub M., Barrett S., Yao T. J., Lepore J., Gilewski T., Currie V., Crown J. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995 Oct;13(10):2575–2581. doi: 10.1200/JCO.1995.13.10.2575. [DOI] [PubMed] [Google Scholar]
  33. Valero V., Jones S. E., Von Hoff D. D., Booser D. J., Mennel R. G., Ravdin P. M., Holmes F. A., Rahman Z., Schottstaedt M. W., Erban J. K. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998 Oct;16(10):3362–3368. doi: 10.1200/JCO.1998.16.10.3362. [DOI] [PubMed] [Google Scholar]
  34. Van Cutsem E., Findlay M., Osterwalder B., Kocha W., Dalley D., Pazdur R., Cassidy J., Dirix L., Twelves C., Allman D. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000 Mar;18(6):1337–1345. doi: 10.1200/JCO.2000.18.6.1337. [DOI] [PubMed] [Google Scholar]
  35. Villalona-Calero M. A., Weiss G. R., Burris H. A., Kraynak M., Rodrigues G., Drengler R. L., Eckhardt S. G., Reigner B., Moczygemba J., Burger H. U. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol. 1999 Jun;17(6):1915–1925. doi: 10.1200/JCO.1999.17.6.1915. [DOI] [PubMed] [Google Scholar]
  36. Weber B. L., Vogel C., Jones S., Harvey H., Hutchins L., Bigley J., Hohneker J. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 1995 Nov;13(11):2722–2730. doi: 10.1200/JCO.1995.13.11.2722. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES